News

The Cross-Cluster Weeks Thuringia were again a complete success in 2021 with almost 800 participants. Topics like sustainable production, new materials, energy transition, resource efficiency, on-site analysis and therapy of infections or digitalization were discussed in a cross-sectoral exchange…

The central German start-up company "nanozoo" – a member of the InfectoGnostics research campus in Jena – has launched a portal for the free analysis and processing of raw data from the genome sequencing of SARS-CoV-2 isolates. Within a few hours, the data of registered users will be processed and…

An international team of researchers, including two InfectoGnostics partners - the Leibniz Institute for Photonic Technologies (Leibniz-IPHT) in Jena and the diagnostics company Senova in Weimar - has developed a rapid antibody test for the new coronavirus. Using a blood sample, it shows within ten…

The right treatment for the right patient at the right time - this approach of "precision medicine" is increasingly being used in the prevention of infections and sepsis. In an interview with the "Infectious Diseases Hub", Prof. Mathias Pletz, leading infectiologist at the University Hospital of…

The Federal Ministry of Education and Research (BMBF) is funding a new Leibniz Research Centre in Jena. Technology developers, physicians and medical technology manufacturers will bring light-based technologies for better diagnostics and therapy of infections from the idea to the application in the…

One in eight newly hospitalised patients is already a carrier of ESBL-forming bacteria, scientists from the InfectoGnostics Research Campus Jena have now proven in an observational study involving 1,334 patients. Although infections with the patient’s own ESBL pathogens remained an exception in the…

The InfectoGnostics Research Campus Jena presented itself at this year's MEDICA trade fair in Düsseldorf from November 12 to 15, 2018. The "RamanBioAssay" for photonic detection of antibiotic resistance was presented at the joint Middle German stand "Forschung für die Zukunft / Research for the…

The Geneva Foundation for Innovative New Diagnostics (FIND) will fund feasibility studies on molecular point-of-care tests for hepatitis C by the two InfectoGnostics industrial partners Abbott (Alere Technologies) and BLINK. This was announced by FIND on 28 July, World Hepatitis Day.

The Jena scientists Prof. Ute Neugebauer and Prof. Juergen Popp were awarded the 3rd prize of the Berthold Leibinger Innovationspreis 2018 for their light-based method for the rapid determination of antibiotic resistance.

The “CarbDetect AS-2” molecular resistance test is the first product developed through collaboration at the InfectoGnostics research campus. A clinical study in Pakistan now shows that this cost-effective test meets the requirements for use in clinical laboratories: With a reliability of 98.8%, the…